The randomised, double-blind, placebo-controlled trial assessed Lacticaseibacillus rhamnosus CRL1505 for prevention of upper respiratory tract infections in healthy adults.

The analysis found reductions in episode number and duration, symptomatic medication and antibiotic use, with a stronger signal among participants with recurrent infections. Time to first infection was not significantly different.

For industry, the study makes the structure of probiotic evidence visible: strain identification, dose, duration, population and endpoint cannot be separated from the result.

The findings cannot be assigned to other strains of the same species, different blends or products with different technological characteristics. Claims and communication must remain anchored to the documented formulation.

Why it matters

The case reminds formulation and marketing teams that species, strain, dose, population and endpoint must remain connected when evidence is transferred to a product.

Evidence limit

Results apply to CRL1505, not probiotics as a category. Some endpoints were secondary and transferability to other formulations is not automatic.

Editorial note. This content is intended for industry professionals. It does not constitute medical advice, therapeutic guidance or regulatory advice. Read our editorial method.

Read the original source · PMC / scientific article ↗